US Generic 'Breakthrough' Pathway Could Have Unintended Consequences
CDER Director Woodcock warns that incentivizing ANDA development with breakthrough-style approach could have unintended consequences, such as more citizen petitions designed to delay generic availability.
You may also be interested in...
Democrats argue generic competition alone cannot fix drug pricing problem as senators attempt to pull FDA into Obamacare repeal and replace debate.
Although panelists expressed concerns about REMS misuse as barrier to competition, Republicans did not appear interested in the topic.
FDA worries about diverting resources to respond to 505(q) petitions, despite receiving lowest number in fiscal year 2015 since it began tracking requests.